An Open-label Study of the Effect of Continuous Xeloda Therapy in Combination With Irinotecan on Treatment Response in Patients With Advanced and/or Metastatic Colorectal Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor measurements (RECIST criteria)
Event driven
No
Clinical Trials
Study Director
Hoffmann-La Roche
United States: Food and Drug Administration
MO16460
NCT00048126
July 2001
January 2005
Name | Location |
---|---|
Birmingham, Alabama 35294 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Albany, New York 12208 | |
Nashville, Tennessee 37203-1632 | |
Albuquerque, New Mexico 87131-5636 | |
Boston, Massachusetts | |
Charlotte, North Carolina | |
Providence, Rhode Island 02908 |